# Transave Inhalation Biopharmaceuticals

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/transave-inhalation-biopharmaceuticals

- Industry: Biotechnology
- Headquarters: US
- Website: www.transaveinc.com
- Total disclosed funding: $67M
- Latest round: Series D (Mar 31, 2008)
- Investors on record: 9

## About

Transave Inhalation Biopharmaceuticals is a US-based company that operates as a provider of inhaled pharmaceuticals for the treatment of lung diseases.

## Funding rounds

- Series D, Mar 31, 2008, $35M — Prospect Venture Partners, Quaker Partners Management, TVM Capital Life Science, Easton Capital Investment Group, Bessemer Venture Partners, F-Prime Capital, Forbion
- Series D, Dec 12, 2007, $15M — Prospect Venture Partners, Easton Capital Investment Group, Bessemer Venture Partners, F-Prime Capital, Forbion, TVM Capital
- Series C, Mar 3, 2006, $17M — AAC Capital Partners, Prospect Venture Partners, Easton Capital Investment Group, F-Prime Capital, TVM Capital
- Series B, Dec 1, 2002 — Forbion

## Investors

- Forbion (https://capitalatlas.ai/funds/forbion) — Series B, Series D
- AAC Capital Partners (https://capitalatlas.ai/funds/aac-capital-partners) — Series C
- Prospect Venture Partners (https://capitalatlas.ai/funds/prospect-venture-partners) — Series C, Series D
- Easton Capital Investment Group (https://capitalatlas.ai/funds/easton-capital-investment-group) — Series C, Series D
- F-Prime Capital (https://capitalatlas.ai/funds/f-prime-capital) — Series C, Series D
- TVM Capital (https://capitalatlas.ai/funds/tvm-capital) — Series C, Series D
- Bessemer Venture Partners (https://capitalatlas.ai/funds/bessemer-venture-partners) — Series D
- Quaker Partners Management (https://capitalatlas.ai/funds/quaker-partners-management) — Series D
- TVM Capital Life Science (https://capitalatlas.ai/funds/tvm-capital-life-science) — Series D